menu search

renalytix: high growth artificial intelligence play, nearing a possible breakout

renalytix has transformative, proprietary machine learning medical technology that is vastly improving ...

April 5, 2022, 3:38 pm

renalytix plc (rnlx) ceo james mccullough on q2 2022 results - earnings call transcript

renalytix Plc (RNLX) CEO James McCullough on Q2 2022 Results - Earnings Call Transcript...

March 31, 2022, 3:45 pm

Neurocrine biosciences to present data on treatment patterns and unmet needs in adult and pediatric patients living with classic congenital adrenal hyperplasia at amcp 2022

SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patt...

March 28, 2022, 8:30 am

4d pharma shares soar on mrx0518/keytruda combo trial data in renal cell carcinoma

4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE:...

March 23, 2022, 9:43 am

Cincor pharma to report fourth quarter and full year 2021 financial results and host conference call on march 22, 2022

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its le...

March 15, 2022, 9:41 am

Aravive highlights updated batiraxcept data from kidney cancer trial

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell ...

March 3, 2022, 10:06 am

Aravive highlights updated batiraxcept data from kidney cancer trial

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell ...

March 3, 2022, 10:06 am

Aravive highlights updated batiraxcept data from kidney cancer trial

Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell ...

March 3, 2022, 10:06 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Alkermes' nemvaleukin shows encouraging anti-tumor activity in pretreated kidney cancer

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) va...

February 17, 2022, 11:23 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am

Aveo oncology to present positive new long-term pfs data from phase 3 tivo-3 study of fotivda® (tivozanib) in third- and fourth-line renal cell carcinoma

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)...

February 14, 2022, 5:01 pm

Aveo oncology to present positive new long-term pfs data from phase 3 tivo-3 study of fotivda® (tivozanib) in third- and fourth-line renal cell carcinoma

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)...

February 14, 2022, 5:01 pm

Aveo oncology to present positive new long-term pfs data from phase 3 tivo-3 study of fotivda® (tivozanib) in third- and fourth-line renal cell carcinoma

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)...

February 14, 2022, 5:01 pm

Merck (mrk) keytruda gets eu nod for expanded kidney cancer use

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinom...

January 28, 2022, 12:19 pm

Merck (mrk) keytruda gets eu nod for expanded kidney cancer use

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinom...

January 28, 2022, 12:19 pm

Merck (mrk) keytruda gets eu nod for expanded kidney cancer use

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinom...

January 28, 2022, 12:19 pm


Search within

Pages Search Results: